Stockreport

Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies

Cognition Therapeutics, Inc.  (CGTX) 
PDF PURCHASE, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs th [Read more]